Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2542 for:    SElect early

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03784066
Recruitment Status : Recruiting
First Posted : December 21, 2018
Last Update Posted : December 21, 2018
Sponsor:
Collaborators:
AstraZeneca
European Organisation for Research and Treatment of Cancer - EORTC
Vlaams Instituut voor Biotechnologie (VIB)
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

Brief Summary:
This is a randomized, open-label, prospective, pilot phase I/II study with focus on translational research and on the evaluation of the biological changes that are observed in sequential tumor tissue acquisition in patients with newly diagnosed advanced (stage IV) oral cavity SCC. Patients are treated with Durvalumab (arm A) or Durvalumab + Tremelimumab (arm B) after biopsy-confirmed diagnosis of locally advanced resectable SCCHN of the oral cavity. After surgery, the standard of care treatment is radiotherapy, and, depending on risk assessment concurrent cisplatin. Patients will be treated with Durvalumab (arm A) or Durvalumab and Tremelimumab (arm B) during six additional cycles, starting from day one of the postoperative radiotherapy.

Condition or disease Intervention/treatment Phase
Oral Cavity Squamous Cell Carcinoma Drug: Durvalumab Combination Product: Durvalumab + Tremelimumab Phase 1 Phase 2

Detailed Description:

Durvalumab has shown activity in squamous cell carcinoma of the head and neck. Locally advanced resectable cancers of this type represent a challenge, as the majority of these patients still die from this disease in spite of surgery, radio- and chemotherapy.

Checkpoint inhibitors have recently proven to prolong life in recurrent/metastatic SCCHN, and several new molecules are currently tested in clinical trials in this indication, including PD-1, PD-L1, and CTLA-4 antibodies, either as single agent or in combination. These compounds might represent a valuable treatment for SCCHN patients in the adjuvant setting, given the favorable toxicity profile. Combination of Durvalumab (PD-L1 inhibition) and Tremelimumab (CTLA-4 inhibition) is currently tested in recurrent/metastatic head and neck cancer, and compared to Durvalumab as single agent, and to standard of care chemotherapy.

In this study both options, i.e. durvalumab as a single agent or Durvalumab in combination with Tremelimumab, will be tested in a randomized fashion. Randomization would be used to reduce selection bias, in a non-comparative study. Newly diagnosed patients with SCCHN of the oral cavity, will be treated with a single dose of Durvalumab with or without Tremelimumab two weeks before scheduled surgery.

When patients are first diagnosed with a resectable oral SCC, a biopsy is taken to confirm the diagnosis, and surgery is planned. This standard practice thus involves sequential tissue harvesting, both at the time of biopsy as well as the final resection specimen, making it possible to observe hallmarks of immune response when patients are treated once with Durvalumab with or without Tremelimumab after confirmation of the diagnosis on biopsy, but before surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The primary objective is to evaluate the biological response in the tumor upon treatment with Durvalumab, and in parallel, with combination of Durvalumab and Tremelimumab.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Durvalumab (MEDI4736) Plus Tremelimumab in Resectable, Locally Advanced Squamous Cell Carcinoma of the Oral Cavity: a Window of Opportunity Study
Actual Study Start Date : August 27, 2018
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : March 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Active Comparator: A
Durvalumab
Drug: Durvalumab

All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).

In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).

Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative.


Active Comparator: B
Durvalumab + Tremelimumab
Combination Product: Durvalumab + Tremelimumab

All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).

In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).

Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative.





Primary Outcome Measures :
  1. Evaluation of biological response in tumor tissue by means of difference in CD8 lymfocyte infiltration density [ Time Frame: The first biopsy will be harvested as part of the diagnostic screening procedures between day 28 and 14 before surgery. The second biopsy will be harvest from the resection specimen on day 0. IP will be given exactly 14 days before surgery. ]
    Difference in CD8 infiltration density will be evaluated on Formalin-Fixed Paraffin-Embedded sections. Measurements will be done both visually by trained pathologists and quantitative on immunofluorescence panel.


Secondary Outcome Measures :
  1. Imaging [ Time Frame: After 14 days of treatment, prior to surgery ]
    RECIST v1.1 will be used to compare MRI images to preoperative imaging in order to non-invasively detect potential radiological changes induced by the investigated drug.

  2. 68Ga-CXCR-4 PET/MR (optional) [ Time Frame: After 14 days of treatment, prior to surgery ]

    RECIST v1.1 will be used to compare MRI images (as part of the 68Ga-CXCR-4 PET/MR) to preoperative imaging in order to:

    • assess the correlation of metabolic 68Ga-CXCR-4 PET/MR with immune response in the tumor
    • identify an imaging technique able to detect immunologic activity that could serve as an imaging biomarker to select early those patients that may benefit from durvalumab with or without tremelimumab.

  3. Locoregional control in days [ Time Frame: Up to 2 years after surgery ]
    Patient follow up according to standard of care will include locoregional control, measured in days.

  4. Time to treatment failure in days [ Time Frame: Up to 2 years after surgery ]
    Patient follow up according to standard of care will include time to treatment failure, measured in days.

  5. Overall survival in days [ Time Frame: Up to 5 years after surgery ]
    Overall survival will be measured in days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Resectable locally advanced oral cavity SCC stage IV
  • Newly diagnosed disease
  • Age ≥18 years at the time of screening
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
  • No active second malignancy during the last five years except non melanomatous skin cancer or carcinoma in situ of the cervix
  • No prior chemotherapy, radiotherapy or targeted therapy including PD-1, PD-L1 or CTLA-4 antibodies for SCCHN, including durvalumab or tremelimumab
  • Availability of blood samples for Translational research
  • Negative pregnancy test
  • Normal organ function
  • No participation in another interventional clinical trial in the preceding 30 days prior to randomization
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations
  • Body weight > 30 kg

Exclusion Criteria:

  • Histologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck
  • Receipt of other treatments for cancer within 30 days prior to first dose of study treatment
  • Previous radiotherapy in the head and neck region
  • Previous systemic therapy for SCCHN
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of their assigned IP.
  • History of allogeneic organ transplantation
  • Active or prior documented autoimmune or inflammatory
  • Uncontrolled intercurrent illness
  • Active relevant second malignancy during the last five years
  • Mean QT interval corrected for heart rate ≥470 ms
  • History of active primary immunodeficiency
  • Active infection Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP.
  • Female patients of childbearing potential who are pregnant or breast-
  • Known allergy or hypersensitivity to IP or any IP excipient
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the IP or interpretation of patient safety or study results
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP
  • Metastatic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03784066


Contacts
Layout table for location contacts
Contact: Paul Clement, Prof. +32 16 34 69 00 paul.clement@uzleuven.be
Contact: Michel Bila, Dr. +32 16 33 24 62 michel.bila@uzleuven.be

Locations
Layout table for location information
Belgium
UZ Leuven Recruiting
Leuven, Belgium, 3000
Contact: Paul Clement, Prof.       paul.clement@uzleuven.be   
Contact: Michel Bila, Dr.       michel.bila@uzleuven.be   
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
AstraZeneca
European Organisation for Research and Treatment of Cancer - EORTC
Vlaams Instituut voor Biotechnologie (VIB)
Investigators
Layout table for investigator information
Principal Investigator: Paul Clement, Prof. UZ Leuven
Layout table for additonal information
Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT03784066    
Other Study ID Numbers: ESR-16-12192
2017-000577-36 ( EudraCT Number )
First Posted: December 21, 2018    Key Record Dates
Last Update Posted: December 21, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Universitaire Ziekenhuizen Leuven:
squamous cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Durvalumab
Tremelimumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs